Latest Commercial Expansion News

ReNerve Limited reported a half-year loss of $2.72 million, up 47% from last year, as it expands its nerve repair product portfolio and secures new regulatory approvals in Asia-Pacific.

First Graphene Limited reported a strong 53% revenue increase driven by new industrial applications, yet posted a $3.35 million net loss influenced by non-cash finance costs. The company’s recent $3.5 million capital raise positions it to focus on commercial expansion without further funding.

Immuron Limited reported a narrower half-year loss alongside record sales growth and FDA approval for its IMM-529 drug candidate, signalling promising clinical and commercial momentum.

Imricor Medical Systems saw a sharp 69.5% decline in revenue for 2025, driven by clinical trial impacts, yet narrowed its net loss to $25.3 million as it secured FDA clearance for key products post-year-end.

OncoSil Medical has reported record dose sales and cash receipts in the first half of FY26, supported by encouraging clinical trial results and expanded European market penetration.

Telix Pharmaceuticals delivered a strong 56% revenue increase in 2025, driven by U.S. sales of Illuccix and the launch of Gozellix, while advancing its therapeutic pipeline and expanding global manufacturing capabilities. Despite a net loss, the company is investing heavily in R&D and sustainability initiatives aligned with climate-related disclosures.

Orthocell has secured a $3 million R&D tax refund, lifting its cash reserves to nearly $50 million and reinforcing its financial strength as it pushes commercialisation of its nerve repair product Remplir™ across key global markets.

Adherium Limited launches a A$7.52 million equity raising to fund commercial expansion of its Hailie SmartInhaler remote patient monitoring platform targeting asthma and COPD patients in the US. The company aims to scale patient numbers and progress towards value-based care contracts with major insurers.

Eden Innovations has taken a major step in strengthening its balance sheet by converting a $2.2 million loan into equity, positioning the company debt free and ready to accelerate growth.

Algorae Pharmaceuticals has secured a key Licence & Supply Agreement with Cadila Pharmaceuticals to commercialise two generic cardiovascular and metabolic medicines in Australia and New Zealand, broadening its therapeutic reach beyond oncology.

Osteopore Limited has successfully raised the entire $5 million from the first tranche of its $20 million convertible notes issuance, securing funds to support ongoing operations and future growth.

Memphasys has raised $800,000 through a share placement to accelerate the commercial expansion of its Felix™ System, following key regulatory approvals and initial revenue milestones.